THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, March 27, 2020
Critical reagents aid in the developer's comprehension of a molecule's performance throughout the development life cycle. A vital reagent management strategy should be established early to ensure reliable results.
FREMONT, CA: Critical reagents are critical in creating prominent molecule drugs. They are a crucial component of the bioanalytical assay used to quantify the test chemical. Businesses frequently struggle to generate and manage large quantities of consistent quality, although such consistency is required to ensure the assay's accuracy, precision, and robustness.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Development teams must employ a robust management plan for the program's success. Drug development can take up to ten years—plenty of time for crucial reagents to expire or become depleted. As a result of the unavoidable lot variations, management issues of all sizes may arise, as the biological nature of essential chemicals makes them prone to unpredictability.
On the other hand, significant alterations may include altering the process of producing antibodies or utilizing a new source for monoclonal antibody production. Pharmaceutical developers should establish validation procedures for determining the variation between lots. According to the ICH M10 recommendations, a necessary reagent lifecycle management procedure is required to assure consistency between original and new batches of critical reagents.
Best approaches for managing essential reagents
The Food and Drug Administration (FDA) of the United States and the American Association of Pharmaceutical Scientists (AAPS) propose management best practices. Their key direction to developers is to prioritize characterizing and documenting their work. According to the FDA's Bioanalytical Method Validation (BMV) advice, "assay validation is required when crucial reagents are changed, such as lot-to-lot alterations or reagent switches."
Additionally, the guideline states that if the labeled analytes, detector reagents, or antibodies are changed, the sponsor should evaluate binding and adjust assays as necessary, verify performance using a standard curve and quality control procedures, and conduct a cross-reactivity analysis.
The AAPS also describes managing critical reagents, including reagent design, stability assignment, and procedure adjustments for minor and substantial alterations. The processes used to respond to minor changes can also serve as a baseline for responding to significant changes.
These core management actions are designed to validate the assay's functionality. Regulatory standards for pharmacology or biomarkers require three stages of quality control. Developers should conduct many runs if multiple reagents need to be modified. Laboratories should not begin documenting until they have monitored instrument performance and compared results to the original lot. Finally, developers should do three runs to document assay performance. Labeling enables the identification of differences between batches and the determination of whether to perform a complete or partial validation.
Bridging testing is critical during lot modifications. Inconsistent performance can indicate a variation that could affect test results. If the assay's performance is altered or acceptance requirements are not fulfilled, developers may be able to validate the batch. Understanding how this new lot affects assay parameters is vital for data integrity.
More in News